updated 6/7/2011 7:16:38 AM ET 2011-06-07T11:16:38

DALLAS, June 7, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring OXiGENE Inc. (Nasdaq:OXGN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/OXGN

OXiGENE (OXGN) is a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs) that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company currently has three ongoing VDA drug development programs that address cancer and ophthalmology indications. Its VDA product candidates, as described in scientific publications and presentations, have demonstrated significant potential in human clinical studies to date in cancer and eye disease. ZYBRESTAT, the Company's lead candidate, is being evaluated in studies of patients with anaplastic thyroid cancer (ATC), non-squamous non-small cell lung cancer and platinum-sensitive ovarian cancer.

This newsletter has been helping traders make great investment decisions on OXGN; click here for a 25% discount offer.

In the report, the analyst notes:

"Drug maker OXGN saw its stock rise over 7% in Monday's trading after the Company announced that it is again in compliance with certain Nasdaq minimum market and stock value requirements, which allows the Company to continue to trade on the exchange."

"Investors also welcomed the news of encouraging data from the Company's phase ll/III trial of ZYBRESTAT (fosbretabulin tromethamine, or CA4P). The Company yesterday announced that it presented final results from a randomized, controlled phase II/III study of ZYBRESTAT in patients with anaplastic thyroid cancer (ATC) at this year's meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois."

To read the entire report visit: www.microstockprofit.com/lp/OXGN

See what investors are saying about OXGN at http://www.stockhideout.com

Get breaking news on OXGN at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Jay Geller
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.93%
$30K home equity loan FICO 5.20%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.13%
17.11%
Source: Bankrate.com